IP Group (LSE:IPO) - Aandelenkoers, Nieuws & Analyse

IPO Overzicht aandelen

IP Group Plc is een participatie- en durfkapitaalbedrijf dat gespecialiseerd is in seed/startup, early venture, emerging growth, mature, mid venture, late venture, incubatie, mezzanine in groeikapitaalbedrijven. Meer informatie

IPO fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 106.56% per jaar groeien

Risicoanalyse

Heeft een omzet van minder dan 1 miljoen USD ( £-213M )

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

IP Group Plc Concurrenten

Molten Ventures

LSE:GROW

UK£594.5m

Arix Bioscience

LSE:ARIX

UK£176.5m

Octopus Renewables Infrastructure Trust

LSE:ORIT

UK£399.8m

Symphony International Holdings

LSE:SIHL

US$156.1m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor IP Group
Historische aandelenkoersen
Huidige aandelenkoers	UK£0.43
52 Week Hoogtepunt	UK£0.61
52 Week Laag	UK£0.36
Bèta	1.39
11 maand verandering	-7.71%
3 maanden verandering	2.25%
1 Jaar Verandering	-18.06%
33 jaar verandering	-62.65%
5 jaar verandering	-28.05%
Verandering sinds IPO	-34.70%

Recent nieuws en updates

Recent updates

What Type Of Shareholders Make Up IP Group Plc's (LON:IPO) Share Registry?

Dec 10

Rendement voor aandeelhouders

	IPO	GB Capital Markets	GB Markt
7D	3.9%	3.4%	2.2%
1Y	-18.1%	28.2%	8.8%

Rendement versus industrie: IPO presteerde slechter dan de UK Capital Markets -sector, die het afgelopen jaar een rendement van 26.5 % opleverde.

Rendement versus markt: IPO presteerde slechter dan UK Market, dat het afgelopen jaar een rendement van 8.3 % opleverde.

Prijsvolatiliteit

Is IPO's price volatile compared to industry and market?
IPO volatility
IPO Average Weekly Movement	5.3%
Capital Markets Industry Average Movement	3.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: IPO heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van IPO is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2001	95	Greg Smith	www.ipgroupplc.com

IP Group Plc is een private-equity- en durfkapitaalonderneming die gespecialiseerd is in seed/startups, early venture, emerging growth, mature, mid venture, late venture, incubatie, mezzanine in groeikapitaalbedrijven. Het investeert bij voorkeur in energie, materialen, gezondheidszorg, informatietechnologie, communicatiediensten, nutsbedrijven, biowetenschappen, deeptech, cleantech, chemicaliën, wetenschap en innovatiebedrijven. Het bedrijf investeert bij voorkeur in Europa.

IP Group Plc Samenvatting

Hoe verhouden de winst en inkomsten van IP Group zich tot de beurswaarde?
IPO fundamentele statistieken
Marktkapitalisatie	UK£426.49m
Inkomsten(TTM)	-UK£226.30m
Inkomsten(TTM)	n/a

-2.0x

P/S-verhouding

-1.9x

Koers/Winstverhouding

Is IPO overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IPO resultatenrekening (TTM)
Inkomsten	-UK£212.50m
Kosten van inkomsten	UK£0
Brutowinst	-UK£212.50m
Overige uitgaven	UK£13.80m
Inkomsten	-UK£226.30m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.23
Brutomarge	100.00%
Nettowinstmarge	106.49%
Schuld/Eigen Vermogen Verhouding	14.2%

Hoe presteerde IPO op de lange termijn?

Bekijk historische prestaties en vergelijking

IPO Overzicht aandelen

Beloningen

Risicoanalyse

IP Group Plc Concurrenten

LSE:GROW

UK£594.5m

LSE:ARIX

UK£176.5m

LSE:ORIT

UK£399.8m

LSE:SIHL

US$156.1m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Dr. Falk Pharma GmbH acquired Kynos Therapeutics Ltd from Epidarex Capital, IP Group Plc (LSE:IPO) and Scottish Investment Bank Limited.

Visa Inc. (NYSE:V) signed a definitive agreement to acquire Featurespace from from Chrysalis Investments Limited (LSE:CHRY), Highland Europe (UK) LLP, IP Group Plc (LSE:IPO), Insight Venture Management, LLC, MissionOG Capital, LLC, and TTV Capital LLC.

Visa Inc. (NYSE:V) signed a definitive agreement to acquire Featurespace from from Chrysalis Investments Limited (LSE:CHRY), Highland Europe (UK) LLP, IP Group Plc (LSE:IPO), Insight Venture Management, LLC, MissionOG Capital, LLC, and TTV Capital LLC.

First half 2024 earnings released: UK£0.11 loss per share (vs UK£0.053 loss in 1H 2023)

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 99%

Recent updates

Dr. Falk Pharma GmbH acquired Kynos Therapeutics Ltd from Epidarex Capital, IP Group Plc (LSE:IPO) and Scottish Investment Bank Limited.

Visa Inc. (NYSE:V) signed a definitive agreement to acquire Featurespace from from Chrysalis Investments Limited (LSE:CHRY), Highland Europe (UK) LLP, IP Group Plc (LSE:IPO), Insight Venture Management, LLC, MissionOG Capital, LLC, and TTV Capital LLC.

Visa Inc. (NYSE:V) signed a definitive agreement to acquire Featurespace from from Chrysalis Investments Limited (LSE:CHRY), Highland Europe (UK) LLP, IP Group Plc (LSE:IPO), Insight Venture Management, LLC, MissionOG Capital, LLC, and TTV Capital LLC.

First half 2024 earnings released: UK£0.11 loss per share (vs UK£0.053 loss in 1H 2023)

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 99%

IP Group Plc to Report First Half, 2024 Results on Sep 17, 2024

Forcepoint LLC entered into a definitive agreement to acquire Garrison Technology Limited from IP Group Plc (LSE:IPO).

Price target decreased by 15% to UK£1.13

CEO & Executive Director recently sold UK£98k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

IP Group Plc, Annual General Meeting, Jun 12, 2024

New minor risk - Financial data availability

IP Group Plc to Report Fiscal Year 2023 Results on Mar 13, 2024

IP Group Plc (LSE:IPO) commences an Equity Buyback Plan for 103,677,065 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Price target increased by 7.5% to UK£1.32

First half 2023 earnings released: UK£0.052 loss per share (vs UK£0.30 loss in 1H 2022)

Now 21% undervalued

IP Group Plc to Report First Half, 2023 Results on Aug 02, 2023

Price target decreased by 8.8% to UK£1.18

Full year 2022 earnings released: UK£0.33 loss per share (vs UK£0.42 profit in FY 2021)

Now 24% undervalued

IP Group Plc to Report Fiscal Year 2022 Results on Mar 08, 2023

Scaleworks Inc. acquired Import.io Ltd.

IP Group plc Appoints Anita Kidgellas an Independent Non-Executive Director

Now 21% undervalued

Insufficient new directors

Insufficient new directors

Ip Group plc Announces the Initiation of Its Phase 2B Trial of Mbs2320, Its Lead Drug in Rheumatoid Arthritis, with the First Patients Now Dosed

Price target decreased to UK£1.32

First half 2022 earnings released

IP Group Plc Declares an Interim Dividend in Respect of the Period from 1 January 2022 to 30 June 2022, Payable on or Around 19 September 2022

IP Group Plc to Report First Half, 2022 Results on Aug 03, 2022

IP Group Plc Launches 'Kiko Ventures' Platform to Deepen Its Support for Transformative Climate Technology

Price target decreased to UK£1.47

Price target decreased to UK£1.47

Full year 2021 earnings: EPS and revenues exceed analyst expectations

IP Group Plc to Report Fiscal Year 2021 Results on Mar 16, 2022

Insider recently bought UK£61k worth of stock

Investor sentiment improved over the past week

First half 2021 earnings released: EPS UK£0.11 (vs UK£0.011 in 1H 2020)

NeoGenomics Laboratories, Inc. completed the acquisition of remaining 88.95% stake in Inivata Limited from a group of sellers.

IP Group Plc Announces Inaugural Dividend, Payable on 16 June 2021

Full year 2020 earnings released: EPS UK£0.17 (vs UK£0.071 loss in FY 2019)

Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited.

Full year 2020 earnings released: EPS UK£0.17 (vs UK£0.071 loss in FY 2019)

Revenue and earnings beat expectations

IP Group Plc, Annual General Meeting, Jun 09, 2021

Price target raised to UK£1.43

IP Group Plc to Report Fiscal Year 2020 Results on Mar 10, 2021

New 90-day high: UK£1.18

Centessa Pharmaceuticals Limited acquired ApcinteX from Medicxi Ventures (UK) LLP, Touchstone Innovations Plc, Cambridge Enterprise Seed Funds and IP Group Plc (LSE:IPO).

Price target raised to UK£1.24

New 90-day high: UK£0.99

What Type Of Shareholders Make Up IP Group Plc's (LON:IPO) Share Registry?

New 90-day high: UK£0.94

New 90-day high: UK£0.85

New 90-day high: UK£0.85